CA2956814A1 - Rgma fragment based diagnostic assay - Google Patents

Rgma fragment based diagnostic assay Download PDF

Info

Publication number
CA2956814A1
CA2956814A1 CA2956814A CA2956814A CA2956814A1 CA 2956814 A1 CA2956814 A1 CA 2956814A1 CA 2956814 A CA2956814 A CA 2956814A CA 2956814 A CA2956814 A CA 2956814A CA 2956814 A1 CA2956814 A1 CA 2956814A1
Authority
CA
Canada
Prior art keywords
rgma
rgma fragment
kda
fragment
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2956814A
Other languages
English (en)
French (fr)
Inventor
Stefan Barghorn
Berhard K. Muller
Martin Schmidt
Andreas Striebinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Deutschland GmbH and Co KG
Original Assignee
AbbVie Deutschland GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Deutschland GmbH and Co KG filed Critical AbbVie Deutschland GmbH and Co KG
Publication of CA2956814A1 publication Critical patent/CA2956814A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
CA2956814A 2014-09-10 2015-09-09 Rgma fragment based diagnostic assay Abandoned CA2956814A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462048745P 2014-09-10 2014-09-10
US62/048,745 2014-09-10
PCT/EP2015/070603 WO2016038084A1 (en) 2014-09-10 2015-09-09 Rgma fragment based diagnostic assay

Publications (1)

Publication Number Publication Date
CA2956814A1 true CA2956814A1 (en) 2016-03-17

Family

ID=54064367

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2956814A Abandoned CA2956814A1 (en) 2014-09-10 2015-09-09 Rgma fragment based diagnostic assay

Country Status (10)

Country Link
US (3) US20160069907A1 (enExample)
EP (1) EP3191847A1 (enExample)
JP (1) JP6879905B2 (enExample)
CN (2) CN113267630A (enExample)
AU (2) AU2015314240A1 (enExample)
BR (1) BR112017004883A2 (enExample)
CA (1) CA2956814A1 (enExample)
MX (2) MX385216B (enExample)
TW (2) TW202119030A (enExample)
WO (1) WO2016038084A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120118002A (ko) * 2009-12-08 2012-10-25 애보트 게엠베하 운트 콤파니 카게 망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
US20210269535A1 (en) 2018-07-19 2021-09-02 The University Of Tokyo Therapeutic or prophylactic agent for htlv-1-associated myelopathy (ham), and method for treating ham
CN118767130A (zh) * 2020-01-15 2024-10-15 国立大学法人大阪大学 糖尿病性自主神经障碍的预防或治疗剂
CN112402554B (zh) * 2020-10-26 2022-03-01 中国中医科学院广安门医院 一种治疗脑白质病的中药组合物及其应用
US12306192B2 (en) 2021-02-08 2025-05-20 Cedars-Sinai Medical Center Method of detecting cognitive impairment
EP4374300A4 (en) * 2021-07-23 2025-06-11 Cedars-Sinai Medical Center Methods and systems for the early detection of ocular and/or neurological conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE312349T1 (de) * 1998-07-03 2005-12-15 Innogenetics Nv Differentielle diagnose von neurodegeneration
ES2390425T3 (es) * 2000-12-22 2012-11-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
KR20120118002A (ko) * 2009-12-08 2012-10-25 애보트 게엠베하 운트 콤파니 카게 망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
KR20170102378A (ko) * 2009-12-09 2017-09-08 미쓰비시 타나베 파마 코퍼레이션 Ｔ 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 ｔ 세포 활성화 저해 물질의 스크리닝 방법
US8735546B2 (en) * 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012047706A2 (en) * 2010-10-06 2012-04-12 Massachusetts Eye & Ear Infirmary Methods for promotiing reinnervation of auditory hair cells
WO2012174666A1 (en) * 2011-06-22 2012-12-27 UNIVERSITé LAVAL Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
EP3369746A1 (en) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents

Also Published As

Publication number Publication date
JP6879905B2 (ja) 2021-06-02
MX385216B (es) 2025-03-14
MX2017003063A (es) 2017-06-14
AU2015314240A1 (en) 2017-02-09
CN113267630A (zh) 2021-08-17
MX2021009528A (es) 2021-09-08
US20220018855A1 (en) 2022-01-20
JP2017526930A (ja) 2017-09-14
BR112017004883A2 (pt) 2017-12-05
CN107076757A (zh) 2017-08-18
TW201617612A (zh) 2016-05-16
TW202119030A (zh) 2021-05-16
WO2016038084A1 (en) 2016-03-17
US20200241012A1 (en) 2020-07-30
EP3191847A1 (en) 2017-07-19
AU2022200160A1 (en) 2022-02-10
US20160069907A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
US20220018855A1 (en) RGMa Fragment Based Diagnostic Assay
Deza et al. Emerging biomarkers and therapeutic pipelines for chronic spontaneous urticaria
US20220057409A1 (en) Combinatorial temporal biomarkers and precision medicines with detection and treatment methods for use in neuro injury, neuro disease, and neuro repair
JP2004527754A (ja) アルツハイマー型痴呆の鑑別診断処理及びその装置
US20160045570A1 (en) Biomarkers predictive of therapeutic responsiveness to ifnb and uses thereof
JP2015504514A (ja) サンフィリポ症候群のためのバイオマーカーおよびそれらの使用
CN115867575A (zh) 用il-33轴结合拮抗剂治疗急性呼吸窘迫综合征
US20240317876A1 (en) Treatment Of Multiple Sclerosis And Neuromyelitis Optica
Zheng et al. Serum levels of brain-derived neurotrophic factor are associated with depressive symptoms in patients with systemic lupus erythematosus
US7709215B2 (en) Method for diagnosing and treating acute joint injury
EP2069521A2 (en) Biomarkers of multiple sclerosis
WO2017176385A1 (en) Compositions and methods for diagnosing and treating brain injury
US20230273220A1 (en) Methods for prediction, detection and monitoring of substanceuse disorders and/or an infection
US20230190967A1 (en) Method and Composition for Evaluating Response to Neurodegenerative Disease Treatment Agent
US20050130233A1 (en) Methods of diagnosing or treating Alzheimer's disease on basis of increased cerebrospinal fluid levels of nerve growth factor
JP2023500711A (ja) 薬物誘発細胞毒性及び鬱病のバイオマーカー
US20250180583A1 (en) Diagnosis markers of parkinson's disease
AU2010313318A1 (en) Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
EP4455672A1 (en) Method and kit for diagnosing and monitoring chronic graft-versus-host disease (cgvhd) using particular cytokine biomarkers
Cheng et al. The Percentage of Neutrophils is Independently Associated with Blood-Brain Barrier (BBB) Disruption in Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease (MOGAD)
Săcărescu et al. Copeptin's role in traumatic brain injury: The promising quest for a new biomarker
Asmaa et al. PO. 1.16 Limbic encephalitis: a rare complication of systemic lupus erythematosus
US20090162854A1 (en) Methods and kits for diagnosis of schizophrenia
Eikelenboom Biological markers in multiple sclerosis related to disease activity and progression

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200908

FZDE Discontinued

Effective date: 20230721